Literature DB >> 22499107

Expanding the spectrum of monoclonal light chain deposition disease in muscle.

Lyle W Ostrow1, Andrea M Corse, Brett M Morrison, Carol A Huff, John A Carrino, Ahmet Hoke, Andrew L Mammen.   

Abstract

INTRODUCTION: The diagnosis of amyloid myopathy is delayed when monoclonal gammopathies are not detected on initial testing and muscle biopsies are nondiagnostic, and the EMG and symptoms can mimic an inflammatory myopathy.
METHODS: Case report of a patient presenting with severe progressive muscle weakness of unclear etiology despite an extensive workup including two nondiagnostic muscle biopsies.
RESULTS: Directed by MRI, a third biopsy revealed amyloid angiopathy and noncongophilic kappa light chain deposition in scattered subsarcolemmal rings and perimysial regions. A serum free light chain (FLC) assay revealed a kappa monoclonal gammopathy, which was not detected by multiple immunofixations.
CONCLUSIONS: The spectrum of immunoglobulin deposition in muscle is similar to other organs. It comprises a continuum that includes parenchymal amyloid deposition, amyloid angiopathy, and noncongophilic Light Chain Deposition Disease (LCDD). We recommend including the FLC assay in the routine investigation for monoclonal gammopathies. This case also highlights the value of MRI-guided muscle biopsy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499107      PMCID: PMC4133774          DOI: 10.1002/mus.23287

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  26 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  Serum free light chain measurements move to center stage.

Authors:  Arthur R Bradwell
Journal:  Clin Chem       Date:  2005-05       Impact factor: 8.327

3.  Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.

Authors:  Batia Kaplan; Marina Ramirez-Alvarado; Laura Sikkink; Sicilia Golderman; Angela Dispenzieri; Avi Livneh; Gloria Gallo
Journal:  Br J Haematol       Date:  2008-11-29       Impact factor: 6.998

Review 4.  Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.

Authors:  J Buxbaum; G Gallo
Journal:  Hematol Oncol Clin North Am       Date:  1999-12       Impact factor: 3.722

5.  An autopsy case of light chain deposition disease.

Authors:  N Kasahara; H Tamura; O Matsumura; R Nagasawa; Y Suzuki; T Ohgida; S Itoyama; T Mitarai; K Isoda
Journal:  Intern Med       Date:  1994-04       Impact factor: 1.271

6.  Electrophysiologic findings in amyloid myopathy.

Authors:  D I Rubin; R C Hermann
Journal:  Muscle Nerve       Date:  1999-03       Impact factor: 3.217

7.  An autopsy case of diffuse myelomatosis associated with systemic kappa light chain deposition disease (LCDD). A patho-anatomical, immunohistochemical and immunobiochemical study.

Authors:  M Toyoda; A Kajita; S Kita; Y Osamura; T Shinoda
Journal:  Acta Pathol Jpn       Date:  1988-04

8.  MRI evaluation of amyloid myopathy.

Authors:  J P Metzler; J L Fleckenstein; C L White; R G Haller; E P Frenkel; R G Greenlee
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

Review 9.  Light chain deposition disease of the liver associated with AL-type amyloidosis and severe cholestasis.

Authors:  G Faa; P Van Eyken; R De Vos; J Fevery; B Van Damme; J De Groote; V J Desmet
Journal:  J Hepatol       Date:  1991-01       Impact factor: 25.083

10.  Amyloid myopathy: a diagnostic challenge.

Authors:  Heli Tuomaala; Mikko Kärppä; Hannu Tuominen; Anne M Remes
Journal:  Neurol Int       Date:  2009-11-16
View more
  6 in total

1.  Skeletal Myopathy as the Initial Manifestation of Light Chain Multiple Myeloma.

Authors:  Mohamed Reda Belkhribchia; Sara Moukhlis; Tarik Bentaoune; Najat Chourkani; Mohamed Zaidani; Mehdi Karkouri
Journal:  Eur J Case Rep Intern Med       Date:  2020-11-20

2.  A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.

Authors:  Fabrizio Accardi; Valentina Papa; Anna Rita Capozzi; Gian Luca Capello; Laura Verga; Cristina Mancini; Eugenia Martella; Roberta Costa; Laura Notarfranchi; Benedetta Dalla Palma; Franco Aversa; Vladimiro Pietrini; Giovanna Cenacchi; Nicola Giuliani
Journal:  Case Rep Hematol       Date:  2018-01-31

Review 3.  Secondary myopathy due to systemic diseases.

Authors:  J Finsterer; W N Löscher; J Wanschitz; S Quasthoff; W Grisold
Journal:  Acta Neurol Scand       Date:  2016-02-25       Impact factor: 3.209

4.  Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.

Authors:  Erina Ono; Akira Ishii; Yoshiaki Higashi; Natsuko Koita; Takashi Ayaki; Katsuya Tanigaki; Shunsuke Takayanagi; Naoya Kondo; Kaoru Sakai; Shuichiro Endo; Hideki Yokoi; Takeshi Matsubara; Sachiko Minamiguchi; Ichizo Nishino; Ryosuke Takahashi; Motoko Yanagita
Journal:  BMC Nephrol       Date:  2021-02-27       Impact factor: 2.388

5.  Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy.

Authors:  Tânia Maia; Rui Bergantim; Henrique Costa; Jorge Pinheiro; Fernanda Trigo
Journal:  Clin Case Rep       Date:  2021-07-16

6.  Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C).

Authors:  Abhisek Swaika; Nicole J Boczek; Neha Sood; Kimberly Guthrie; Eric W Klee; Ankit Agrawal; Elliot L Dimberg; Sikander Ailawadhi
Journal:  Case Rep Genet       Date:  2016-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.